John Pawloski
Hematology · Phoenix, AZNPI 1093899981
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $186,340 of the $246,338 with a category attached, or 75.6%. Genentech USA, Inc. accounts for 81.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $143,318 and has fallen 60.4% since, to $56,751 in 2022.
Across 213 payments — averaging $1156.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$200K
- Takeda Pharmaceuticals U.S.A., Inc.$41K
- Sanofi$2K
- Karyopharm Therapeutics Inc.$2K
- GSK$131
- Novartis$103
What the payments were for
- Consulting fees$8,7554%
- Speaking & faculty fees$186,34076%
- Travel & lodging$46,09819%
- Food & beverage$5,1352%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 170 | $200,271 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $41,472 |
| Sanofi | 3 | $2,421 |
| Karyopharm Therapeutics Inc. | 1 | $1,940 |
| GSK | 4 | $131 |
| Novartis | 1 | $103 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $7,587 |
| Hydroxyurea | 26 | $413 |
| Dexamethasone | 13 | $291 |
| Prednisone | 23 | $167 |
| Oxycodone Hcl | 11 | $110 |
| Acyclovir | 11 | $93 |
Paid to pharmacies, not to this prescriber.
Other hematology in Phoenix
- Joseph MikhaelScottsdale$1.5M
- Rafael FonsecaScottsdale$650K
- Danielle NanceGilbert$86K
- Pierre NoelScottsdale$51K
- Abdullah LadhaScottsdale$17K
- Misam ZawitGoodyear$11K
- Abdulrahman AbonofalGoodyear$1K
- Pedro Camacho MaldonadoGilbert$469
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.